TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05570110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxolone
Description: one capsule of active or placebo in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxolone
Description: one capsule of active or placebo in the evening
Study: NCT06507436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag tablets
Description: Herombopag tablets; dose 1 or dose 2, for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag tablets
Description: Herombopag tablets; dose 1 or dose 2, for 5 days
Study: NCT05309200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCE-205
Description: The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
Study: NCT06507436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag placebo tablets
Description: Herombopag placebo tablets; dose 1 or dose 2, for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag placebo tablets
Description: Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Study: NCT05806541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter therapy
Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
Study: NCT06553651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotechnology Necrosectomy Procedure
Description: Subjects undergo necrosectomy with 1.7 mm flexible cryoprobes, either concurrently with stent placement or post-placement, at the Investigator's discretion. The cryoprobe will freeze the necrotic tissue and extracted en-bloc. A maximum of 4 cryotechnology procedures will be performed, with each procedure aiming for significant debris removal and clinical improvement of walled-off pancreatic necrosis (WOPN) symptoms.
Study: NCT06428058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive sexual health curriculum
Description: This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing the effects on sexual health knowledge, attitudes, and sexual history and counseling skills at medium (6-) and long-term (12 and 24 months) follow-up. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, lesbian, gay, bisexual, and transgender (LGBT) and sexual violence, clinical skills training, ethics, and community resources and cultural considerations.
Study: NCT06254586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: This group received a single session of low-intensity cycling for 20 minutes. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
Study: NCT06329063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Administration of vasopressin (20 IU) (oral spray)
Study: NCT06254586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resisted exercises
Description: This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with 30 sec to 1 minute rest period between sets. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
Study: NCT06575192

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No ADM
Study: NCT06468228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous injection
Study: NCT05095974

Intervention type: DEVICE
Intervention: ultrasonography
Description: Ultrasound assessment will performed with parturient in the supine position using Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz). A C60x 5-2 MHz convex transducer will used for lung ultrasound (Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz).The Echo Comet Score (ECS) will obtained by the 28-rib interspaces technique dividing the chest wall in 12 areas on the left side (from the second to the fourth intercostal space) and 16 (from the second to the fifth intercostal space) on the right anterior and lateral hemithorax.
Study: NCT06468228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT05426733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odevixibat
Description: Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
Study: NCT06465316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Given SC
Study: NCT05302908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NuestraSaludSegura
Description: It blends peer navigation and mHealth
Study: NCT05160597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo image-guided prostate biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal Ultrasonography Guided Biopsy
Description: Undergo standard of care TRUS
Study: NCT06271291

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04994717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous (cIV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous (cIV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-intensity chemotherapy regimen
Description: Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-intensity chemotherapy regimen
Description: Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC chemotherapy regimen
Description: Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
Study: NCT04809740

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluate implementation of navigator-delivered Home ePRO for all cancer patients
Description: evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes
Study: NCT06179511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9829
Description: AZD9829 will be administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9829
Description: AZD9829 will be administered by IV infusion
Study: NCT06030609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's Lactate Crystalloid Solutions
Description: The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: The patient will receive NSS with D5W as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
Study: NCT05065970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felzartamab
Description: anti-CD38+ monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felzartamab
Description: anti-CD38+ monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felzartamab
Description: anti-CD38+ monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04817735

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAVI
Description: TAVI sizing with dedicated algorithm
Study: NCT04372914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BRB Lozenges
Description: Each lozenge is made from 1 gram of freeze-dried black raspberry powder (equivalent to \~5 black raspberries) in the form of a dissolvable slow-release lozenge.
Study: NCT06329063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (oral spray)
Study: NCT06236815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-8-THC
Description: Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
Study: NCT04966481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered on an outpatient basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given intravenously over approximately 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given intravenously over approximately 60 minutes
Study: NCT06800820

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Chondractiv™ Plus (Hydrolyzed chicken cartilage)
Description: One oral dose
Study: NCT06802094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-session balance intervention in virtual reality
Description: Single-session balance intervention (30 minutes) in a virtual reality environment, the Gait Real-time analysis Interactive Lab (GRAIL) or the Computer Assisted Rehabilitation Environment (CAREN) in children with and without Developmental Coordination Disorder (Motek Medical, The Netherlands).
Study: NCT05885204

Intervention type: PROCEDURE
Intervention: Robot-assisted radical cystectomy
Description: Robot-assisted laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Robot-assisted radical cystectomy
Description: Robot-assisted laparoscopic radical cystectomy
Study: NCT06798727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(low-dose)
Description: A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(mid-dose)
Description: A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Hyal Plus
Description: A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
Study: NCT06800573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: including strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior, (2 sets of 10 repetitions per day) and stretching exercises for pectoralis muscles (20seconds hold, 5 repetition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lying posture with progression
Description: Exercise 1, the lying posture with leg extension progression, was aimed to stretch the anterior muscle chain (diaphragm, pectoralis minor, scalene, sternocleidomastoid, intercostalis, iliopsoas, arm, forearm, and hand flexors)(Bonetti et al., 2010).~Exercise 2, the lying posture with flexion of the thighs, was intended to stretch the posterior chain (upper trapezius, levator scapulae, suboccipital, erector spinae, gluteus maximus, ischiotibial, triceps surae, and foot intrinsic muscles).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartphone app exercises
Description: about 50 min a day, 4 days a week for an 8-week period also, performed exercises which were reminded by a smartphone app at predetermined times.
Study: NCT06801860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very brief smoking cessation advice
Description: All participants will receive very brief smoking cessation advice (guided by the AWARD model, assess, warning, refer, and do-it-again) with a smoking cessation information booklet onsite at baseline.
Study: NCT06212115

Intervention type: DIAGNOSTIC_TEST
Intervention: mNGS
Description: metagenomics next generation sequencing
Study: NCT05206188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastering the World of Work (MWW)
Description: Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
Study: NCT05153369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Skills Training
Description: In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Full Intervention
Description: The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
Study: NCT05519449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JANX007
Description: JANX007 is dosed via IV in a 21- or 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JANX007
Description: JANX007 is dosed via IV in a 21- or 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JANX007
Description: JANX007 is dosed via IV in a 21- or 28-day cycle.
Study: NCT05105581

Intervention type: BEHAVIORAL
Intervention: Quality of life scale
Description: 1. To assess the quality of life of patient~2. To assess the degree of OCD
Study: NCT05524623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous microelectrolysis in myofascial trigger points of the trapezius
Description: percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: percutaneous microelectrolysis in myofascial trigger points of the trapezius
Description: percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
Study: NCT05358522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Prescribing Report Cards
Description: Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention.
Study: NCT06801860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very brief smoking cessation advice
Description: All participants will receive very brief smoking cessation advice (guided by the AWARD model, assess, warning, refer, and do-it-again) with a smoking cessation information booklet onsite at baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Participants in the intervention group will receive 1-2 packs of chewing gum over a 1-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing gum usage leaflet
Description: A leaflet of usage tips for chewing gum, including 1) the potential benefits of chewing gum, 2) suitable usage time and dosage, and 3) the proper disposal of used gum.
Study: NCT06800794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Skill Training
Description: 7 sessions including: Hunger and fullness, eating on a budget, traffic light eating plan, menu planning, creating alternatives to food, financial planning, and changing the environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Provisioning
Description: 3 meals a day consisting of low energy dense, nutrient rich, ready to eat, low GI, foods delivered to the participants' homes.
Study: NCT06800989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morphee Device and sophrology sessions
Description: Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist.~Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on C1D1 or within a maximum of 3 weeks following C1D1. The second session (S2) should be conducted within 3 to 4 weeks after the first session.